SEOM–TTCC clinical guideline for nasopharyngeal carcinoma (update 2025)
Nasopharyngeal carcinoma is distinct from other cancers of the head and neck in biology, epidemiology, histology, natural history, and response to treatment. Radiotherapy is the cornerstone of locoregional treatment of non-disseminated disease and, in combination with chemotherapy, improves survival rates. In the case of metastatic disease stages, treatment requires platinum/gemcitabine-based chemotherapy, and patients may achieve a long survival time. In these guidelines (updated in 2025), we summarize current evidence and available therapies for the medical management of advanced nasopharyngeal carcinoma.
Authors
- R. Álvarez Cabellos
- Virginia Arrazubi (ORCID: https://orcid.org/0000-0002-1431-2780)
- Beatriz Castelo Fernández (ORCID: https://orcid.org/0000-0002-5824-9808)
- Beatriz Cirauqui (ORCID: https://orcid.org/0000-0002-0136-8056)
- Leticia Iglesias Rey
- Antonio Rueda Domínguez
- Alberto Carral Maseda
- Almudena García Castaño
- Ricard Mesía
- Jordi Rubió‑Casadevall
Institutions
- Hospital Universitario La Paz (ES)
- Marqués de Valdecilla University Hospital (ES)
- Institut Català d'Oncologia (ES)
- Navarre Institute of Health Research (ES)
- Navarrabiomed (ES)
- Badalona Serveis Assistencials (ES)
- Complexo Hospitalario Universitario A Coruña (ES)
- Hospital Municipal de Badalona (ES)
- Hospital Universitari de Girona Doctor Josep Trueta (ES)
- Hospital Clínico Universitario Virgen de la Victoria (ES)
- Complejo Hospitalario Universitario de Toledo (ES)
- Complejo Hospitalario de Ourense (ES)
- Hospital Universitario de Toledo (ES)
Publication Details
- Journal
- Clinical & Translational Oncology
- Published
- 2026-02-17
- DOI
- https://doi.org/10.1007/s12094-026-04252-5
- Primary Topic
- Head and Neck Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Sociedad Española de Oncología Médica